Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGL | P06737 | 5/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | FABP4 | P15090 | 8/20 | 0.33 |
| ▸ | FABP5 | Q01469 | 6/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.31 |
| ▸ | ECE1 | P42892 | 2/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3365638 | 1.00 | PYGL (0.33) | PYGLALDH1A1CYP2C9FABP4FABP5 | |
| SCHEMBL1403838 | 1.00 | PYGL (0.33) | PYGLALDH1A1CYP2C9FABP4FABP5 | |
| SCHEMBL7229443 | 0.83 | CNR2 (0.33) | PYGLALDH1A1CYP2C9FABP4FABP5 | |
| SCHEMBL4255673 | 0.83 | MAPT (0.45) | ALDH1A1HTT | |
| SCHEMBL4255678 | 0.83 | MAPT (0.45) | ALDH1A1HTT | |
| SCHEMBL5101577 | 0.79 | ALDH1A1 (0.36) | PYGLALDH1A1CYP2C9FABP4FABP5 | |
| SCHEMBL4416357 | 0.79 | ECE1 (0.45) | ALDH1A1FABP4FABP5ECE1 | |
| SCHEMBL4416349 | 0.79 | ECE1 (0.45) | ALDH1A1FABP4FABP5ECE1 | |
| SCHEMBL9752273 | 0.78 | CYP1A2 (0.35) | PYGLALDH1A1CYP2C9FABP4FABP5 | |
| SCHEMBL10062004 | 0.75 | MME (0.36) | ALDH1A1FABP4FABP5CXCR2CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2291351-A1 | ALPHA-MERCAPTO-AMIDES | Novartis AG (CH) | 2011-03-09 | — | — | EP | disclosed |
| EP-2239268-A1 | Dipeptide derivatives | Novartis AG (CH) | 2010-10-13 | — | — | EP | disclosed |
| WO-2009135526-A1 | ALPHA-MERCAPTO-AMIDES | NOVARTIS AG (CH) | 2009-11-12 | — | — | WO | disclosed |
| US-20060058242-A1 | Dipeptide derivatives | FINK CYNTHIA A | 2006-03-16 | — | — | US | disclosed |
| US-6992105-B2 | Dipeptide derivatives | NOVARTIS AG (CH) | 2006-01-31 | — | — | US | disclosed |
| US-20040235754-A1 | Dipeptide derivatives | NOVARTIS AG (CH) | 2004-11-25 | — | — | US | disclosed |
| US-6777443-B2 | Dipeptide derivatives | NOVARTIS AG (CH) | 2004-08-17 | — | — | US | disclosed |
| EP-1392720-A2 | DIPEPTIDE DERIVATIVES HAVING A N-TERMINAL 2-THIOACYL GROUP AS VASOPEPTIDASE INHIBITORS | Novartis AG (CH) | 2004-03-03 | — | — | EP | disclosed |
| US-6613782-B2 | For treating and/or preventing endothelin dependent conditions, e.g. cardio- and cerebro-vascular disorders such as hypertension, vasoconstriction, congestive heart failure, cerebral disorders, respiratory system disorders | NOVARTIS AG (CH) | 2003-09-02 | — | — | US | disclosed |
| US-20020183260-A1 | Dipeptide derivatives | NOVARTIS AG (CH) | 2002-12-05 | — | — | US | disclosed |
| WO-2002092622-A2 | DIPEPTIDE DERIVATIVES HAVING A N-TERMINAL 2-THIOACYL GROUP AS VASOPEPTIDASE INHIBITORS | NOVARTIS AG (CH) | 2002-11-21 | — | — | WO | disclosed |
| US-6423727-B1 | Certain thiol inhibitors of endothelin-converting enzyme | NOVARTIS AG (CH) | 2002-07-23 | — | — | US | disclosed |
| US-20020082218-A1 | Certain thiol inhibitors of endothelin-converting enzyme | LOMBAERT STEPHANE DE (US) | 2002-06-27 | — | — | US | disclosed |
| WO-2001077095-A2 | DERIVATIVES OF ALPHA-MERCAPTOACETAMIDE | NOVARTIS AG (CH) | 2001-10-18 | — | — | WO | disclosed |
| CN-1297453-A | thiol endothelin converting enzyme inhibitors | NOVARTIS AG (CH) | 2001-05-30 | — | — | CN | disclosed |
| EP-1073674-A1 | THIOL INHIBITORS OF ENDOTHELIN-CONVERTING ENZYME | Novartis AG (CH) | 2001-02-07 | — | — | EP | disclosed |
| WO-1999055726-A1 | CERTAIN THIOL INHIBITORS OF ENDOTHELIN-CONVERTING ENZYME | NOVARTIS AG (CH) | 1999-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020183260-A1 | Dipeptide derivatives | ANPEP, ECE1, ECE2 | PYGL 1293/4885ALDH1A1 1737/4885CYP2C9 2550/4885 |
| US-20060058242-A1 | Dipeptide derivatives | ANPEP, ECE2, ECE1 | PYGL 1651/4885ALDH1A1 2788/4885CYP2C9 2618/4885 |
| US-20040235754-A1 | Dipeptide derivatives | ANPEP, ECE1, ECE2 | PYGL 1293/4885ALDH1A1 1737/4885CYP2C9 2550/4885 |
| US-20020082218-A1 | Certain thiol inhibitors of endothelin-converting enzyme | ECE1, ECE2, EDNRB | PYGL 3424/4885ALDH1A1 139/4885CYP2C9 959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.